Shots:

• The first patient has been dosed in the P-I dose escalation study evaluating the PK profile, safety, and tolerability of Orismilast (PDE4 inhibitor) in healthy Chinese patients
• In the previous studies, Orismilast showed a potent and broad anti-inflammatory effect by inhibiting the secretion of Th1 (TNFα and IFNg, Th17 (IL-22 and IL-23), and Th2 (IL-4, IL-5, and IL-13) effector cytokines in human PBMCs, potent inhibition of innate cytokines (IL-1α and IL-1b) was also observed
• Under the 2021 agreement with UNION, Innovent obtain an exclusive right to research, develop and commercialize Orismilast in China (incl. mainland China, Hong Kong, Macao, and Taiwan) for AD and psoriasis

Ref: PRNewswire | Image: Innovent